Monte Rosa Therapeutics, Inc. 13F holders
193 funds reported a position in Monte Rosa Therapeutics, Inc. in their 13F for the quarter ended 30 June 2026, together 93.3 million shares worth $2.26 billion. Against the quarter before, 26 opened a position, 81 added, 58 trimmed and 23 sold out; together they bought a net 5.4 million shares. The largest holders: Price T Rowe Associates Inc., NEA Management Company, LLC and BlackRock, Inc.
Funds holding193+2 on Q1 2026
Shares they held93.3Mworth $2.26 billion
Net bought on the quarter5.4M sharesabout $130.0 million at the funds' values
Funds buying to selling107 to 81opened or added, to cut or sold
Opened 26Added 81Held 27Trimmed 58Sold out 23
What each fund did in GLUE against its 13F for the quarter before; a change under 0.1% of a holding counts as held
Funds reporting a position in GLUE in their 13F, each quarter; hover a bar for the shares they held
Filed so far for the quarter to 30 September 2026
3,241 funds have filed their 13F for the quarter so far; the rest are due by 16 November 2026. Of those, 28 reported a position in Monte Rosa Therapeutics, Inc.: 5 opened one, 8 added, 9 trimmed and 2 sold out, a net 392,551 shares bought.
The largest moves in the name among the funds that have filed, against each fund's previous 13F.
The well-known funds
Of the 44 funds followed here, 6 reported a position in Monte Rosa Therapeutics, Inc. in a 13F for the quarter ended 30 June 2026. The largest: Geode Capital Management, 1.9 million shares worth $45.1 million, 0.0% of its reported book. New this quarter: Duquesne Family Office. Sold out: Millennium Management. In the quarter, 3 funds added or opened a position and 4 trimmed or sold out; together they bought a net 93,705 shares, about $2.3 million at the funds' own value per share on 30 June 2026. A change under 0.1% of a holding counts as held.
| Fund | Shares | Value | Of its book | Change on the quarter | Status | Quarter ended | Filing |
|---|---|---|---|---|---|---|---|
| Geode Capital Management | 1,864,113 | $45.1 million | 0.0% | +323,301 | added | 30 June 2026 | 13F |
| FMR LLC | 934,414 | $22.6 million | 0.0% | -89,890 | trimmed | 30 June 2026 | 13F |
| Duquesne Family Office | 297,600 | $7.2 million | 0.2% | +297,600 | new | 30 June 2026 | 13F |
| Citadel Advisors | 163,571 | $4.0 million | 0.0% | -90,947 | trimmed | 30 June 2026 | 13F |
| Two Sigma Investments | 140,923 | $3.4 million | 0.0% | +121,623 | added | 30 June 2026 | 13F |
| Renaissance Technologies | 102,500 | $2.5 million | 0.0% | -276,600 | trimmed | 30 June 2026 | 13F |
| Millennium Management | 0 | $0 | 0.0% | -191,382 | exited | 30 June 2026 | 13F |
Value is what the fund reported.
Read more
Change is shares against the fund's previous 13F; a fund with one filing read shows no change. 13Fs cover long US positions of managers above $100 million and are filed up to 45 days after the quarter.The largest holders
| Fund | Shares | Share of all | Value | Of its book | Change in shares | Filing |
|---|---|---|---|---|---|---|
| Price T Rowe Associates Inc. | 8,861,171 | 9.50% | $214.4 million | 0.02% | +2,140,983 | 13F |
| NEA Management Company, LLC | 7,692,298 | 8.24% | $186.2 million | 11.72% | no change | 13F |
| BlackRock, Inc. | 6,843,087 | 7.33% | $165.6 million | 0.00% | +1,205,403 | 13F |
| TCG Crossover Management, LLC | 4,622,151 | 4.95% | $111.9 million | 2.69% | no change | 13F |
| Vestal Point Capital, LP | 4,600,000 | 4.93% | $111.3 million | 2.60% | +996,535 | 13F |
| BVF Inc. | 4,460,886 | 4.78% | $108.0 million | 2.76% | no change | 13F |
| Baker Bros. Advisors LP | 4,345,736 | 4.66% | $105.2 million | 0.53% | no change | 13F |
| State Street Corp. | 3,731,416 | 4.00% | $90.3 million | 0.00% | +377,436 | 13F |
| Montanova Capital, LLC | 3,549,539 | 3.80% | $85.9 million | 1.80% | -677,270 | 13F |
| Vanguard Capital Management LLC | 3,412,927 | 3.66% | $82.6 million | 0.00% | +312,682 | 13F |
| Versant Venture Management, LLC | 3,180,780 | 3.41% | $77.0 million | 47.34% | no change | 13F |
| Braidwell LP | 2,451,562 | 2.63% | $59.3 million | 2.28% | -755,012 | 13F |
| Geode Capital Management, LLC | 1,864,113 | 2.00% | $45.1 million | 0.00% | +323,301 | 13F |
| American Century Companies Inc. | 1,622,846 | 1.74% | $39.3 million | 0.02% | -1,186,801 | 13F |
| Marshall Wace, LLP | 1,593,600 | 1.71% | $38.6 million | 0.03% | +160,448 | 13F |
| Aisling Capital Management LP | 1,555,664 | 1.67% | $37.6 million | 7.98% | no change | 13F |
| Nantahala Capital Management, LLC | 1,303,986 | 1.40% | $31.6 million | 0.96% | 13F | |
| Bellevue Group AG | 1,190,000 | 1.28% | $28.8 million | 0.61% | -60,000 | 13F |
| Dimensional Fund Advisors LP | 1,177,488 | 1.26% | $28.5 million | 0.01% | +136,116 | 13F |
| MPM Bioimpact LLC | 1,161,081 | 1.24% | $28.1 million | 1.71% | -15,847 | 13F |
| Silverarc Capital Management, LLC | 1,108,295 | 1.19% | $26.8 million | 2.98% | -893,745 | 13F |
| Jupiter Topco LLC | 1,072,494 | 1.15% | $26.0 million | 0.01% | first 13F | 13F |
| Frazier Life Sciences Management, L.P. | 1,000,000 | 1.07% | $24.2 million | 0.53% | no change | 13F |
| Goldman Sachs Group Inc. | 998,253 | 1.07% | $24.2 million | 0.00% | -3,274 | 13F |
| Woodline Partners LP | 962,884 | 1.03% | $23.3 million | 0.07% | +888,388 | 13F |
| FMR LLC | 934,414 | 1.00% | $22.6 million | 0.00% | -89,890 | 13F |
| Vanguard Portfolio Management LLC | 791,932 | 0.85% | $19.2 million | 0.00% | +275,966 | 13F |
| Morgan Stanley | 789,545 | 0.85% | $19.1 million | 0.00% | +105,482 | 13F |
| Nextech Invest Ltd. | 761,153 | 0.82% | $18.4 million | 0.87% | +456,916 | 13F |
| Opaleye Management Inc. | 745,000 | 0.80% | $18.0 million | 1.63% | new | 13F |
| Northern Trust Corp. | 652,087 | 0.70% | $15.8 million | 0.00% | -174,537 | 13F |
| First Trust Advisors LP | 647,796 | 0.69% | $15.7 million | 0.01% | new | 13F |
| Charles Schwab Investment Management Inc. | 616,310 | 0.66% | $14.9 million | 0.00% | +69,621 | 13F |
| Boone Capital Management LLC | 615,287 | 0.66% | $14.9 million | 3.48% | new | 13F |
| Bridgeway Capital Management, LLC | 552,566 | 0.59% | $13.4 million | 0.23% | +23,868 | 13F |
| AQR Capital Management LLC | 520,648 | 0.56% | $12.6 million | 0.00% | -137,835 | 13F |
| Vanguard Fiduciary Trust Co. | 505,500 | 0.54% | $12.2 million | 0.00% | +98,422 | 13F |
| Parkwood LLC | 505,000 | 0.54% | $12.2 million | 0.88% | no change | 13F |
| Adage Capital Partners GP, L.l.c. | 450,000 | 0.48% | $10.9 million | 0.01% | +200,000 | 13F |
| Kennedy Capital Management LLC | 405,529 | 0.43% | $9.8 million | 0.17% | +373,552 | 13F |
| Ameriprise Financial Inc. | 383,335 | 0.41% | $9.3 million | 0.00% | +347,338 | 13F |
| Alphabet Inc. | 372,474 | 0.40% | $9.0 million | 0.01% | -311,801 | 13F |
| Fisher Asset Management, LLC | 363,520 | 0.39% | $8.8 million | 0.00% | +48,658 | 13F |
| Allspring Global Investments Holdings, LLC | 352,857 | 0.38% | $8.5 million | 0.01% | -39,370 | 13F |
| Empowered Funds, LLC | 329,266 | 0.35% | $8.0 million | 0.04% | +23,868 | 13F |
| Duquesne Family Office LLC | 297,600 | 0.32% | $7.2 million | 0.17% | new | 13F |
| TD Asset Management Inc | 285,936 | 0.31% | $6.9 million | 0.01% | -1,042 | 13F |
| Bank of America Corp. | 254,561 | 0.27% | $6.2 million | 0.00% | -132,981 | 13F |
| Bank of New York Mellon Corp | 222,521 | 0.24% | $5.4 million | 0.00% | +17,834 | 13F |
| Longaeva Partners L.P. | 216,792 | 0.23% | $5.2 million | 0.15% | new | 13F |
The 50 largest of the 193 funds that reported a position in GLUE in their 13F for the quarter ended 30 June 2026, by the value each reported.
Read more
Share of all is the fund's part of all the shares the funds reported. Change is shares against the fund's 13F for the quarter before. A 13F lists a manager's long positions in US-listed shares at the quarter's end. What is a 13F?Options the funds reported on GLUE
| Fund | Option | Shares under the options | Value of those shares | Quarter ended | Filing |
|---|---|---|---|---|---|
| Citadel Advisors | Calls | 8,800 | $212,960 | 30 June 2026 | 13F |
A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost.
Read more
They are not counted in the holdings above. A put gains when the stock falls, a call when it rises, and a fund may hold either to hedge.Schedule 13D and 13G filed on the name, last twelve months
| Filed | Schedule | Who | Holding | Of the class | Event date | Rule or purpose | Filing |
|---|---|---|---|---|---|---|---|
| 14 August 2026 | 13G/A | Montanova Capital, LLC and 5 others | 3.5 million | 4.2% | 30 June 2026 | passive, under 20% (13d-1(c)) | EDGAR |
| 14 August 2026 | 13G | Vestal Point Capital, LP and 3 others | 4.6 million | 5.4% | 30 June 2026 | passive, institutional (13d-1(b)) | EDGAR |
| 8 July 2026 | 13G/A | T. Rowe Price Associates, Inc. and 1 other | 8.9 million | 10.5% | 30 June 2026 | passive, institutional (13d-1(b)) | EDGAR |
| 6 July 2026 | 13D/A | New Enterprise Associates 17, L.P. and 11 others | 6.7 million | 7.9% | 1 July 2026 | The information provided in Item 5(c) is hereby incorporated by reference. Depending on market conditions and other factors, NEA 17 and the Reporting Persons may dispose of additional shares of the Issuer. | EDGAR |
| 15 May 2026 | 13G/A | TCG Crossover GP II, LLC and 9 others | 4.6 million | 5.5% | 31 March 2026 | passive, under 20% (13d-1(c)) | EDGAR |
| 15 May 2026 | 13G/A | Baker Bros. Advisors LP and 7 others | 8.9 million | 10.0% | 31 March 2026 | passive, institutional (13d-1(b)) | EDGAR |
| 15 May 2026 | 13G/A | Biotechnology Value Fund L P and 19 others | 5.1 million | 6.3% | 31 March 2026 | passive, under 20% (13d-1(c)) | EDGAR |
| 22 April 2026 | 13G/A | Adam Goulburn and 17 others | 6.5 million | 8.1% | 31 March 2026 | passive, under 20% (13d-1(c)) | EDGAR |
| 19 March 2026 | 13D/A | New Enterprise Associates 17, L.P. and 11 others | 7.8 million | 9.7% | 17 March 2026 | NEA 17 acquired the NEA 17 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and the other Reporting Persons may dispose of or acq | EDGAR |
| 17 February 2026 | 13G/A | Baker Bros. Advisors LP and 7 others | 4.3 million | 6.7% | 31 December 2025 | passive, institutional (13d-1(b)) | EDGAR |
| 17 February 2026 | 13G/A | Biotechnology Value Fund L P and 19 others | 3.8 million | 5.9% | 31 December 2025 | passive, under 20% (13d-1(c)) | EDGAR |
| 21 January 2026 | 13G/A | Adam Goulburn and 13 others | 5.7 million | 8.7% | 31 December 2025 | passive, under 20% (13d-1(c)) | EDGAR |
| 9 January 2026 | 13D/A | Versant Venture Capital VI, L.P. and 5 others | 2.2 million | 3.4% | 7 January 2026 | EDGAR | |
| 14 November 2025 | 13G/A | Avoro Capital Advisors LLC and 3 others | 0 | 0.0% | 30 September 2025 | passive, institutional (13d-1(b)) | EDGAR |
| 14 November 2025 | 13G/A | T. Rowe Price Associates, Inc. and 1 other | 4.6 million | 7.5% | 30 September 2025 | passive, institutional (13d-1(b)) | EDGAR |
| 12 November 2025 | 13D/A | Versant Venture Capital VI, L.P. and 5 others | 3.3 million | 5.1% | 10 November 2025 | EDGAR | |
| 31 October 2025 | 13G/A | The Vanguard Group and 1 other | 3.0 million | 4.8% | 30 September 2025 | passive, institutional (13d-1(b)) | EDGAR |
A Schedule 13D is filed by anyone who crosses 5% of a class with intent to influence; a 13G by a passive holder.
Read more
Amendments (/A) report a change, including an exit to zero. Holding and percentage are as the filer stated them on the cover page; the purpose is the filer's own words, cut short. 13D and 13GFails to deliver
| Settlement date | Shares failed | Price | File |
|---|---|---|---|
| 23 September 2026 | 18 | $12.60 | SEC |
| 17 September 2026 | 54,787 | $12.65 | SEC |
| 15 September 2026 | 8,665 | $13.90 | SEC |
| 2 September 2026 | 1,482 | $14.31 | SEC |
Shares that failed to deliver at settlement, per day, from the SEC's half-month files, which arrive about two weeks after the period.